Rimadyl Granules 8.75% w/w

Երկիր: Միացյալ Թագավորություն

Լեզու: անգլերեն

Աղբյուրը: VMD (Veterinary Medicines Directorate)

Ակտիվ բաղադրիչ:

Carprofen

Հասանելի է:

Pfizer Ltd

INN (Միջազգային անվանումը):

Carprofen

Լիազորման կարգավիճակը:

Expired

Ապրանքի հատկությունները

Revised: 03 June 2008
AN: 02090/2007
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimadyl Granules 8.75% w/w
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_Active ingredient_
% w/w
Carprofen
8.75
For full list of excipients, see Section 6.1
3.
PHARMACEUTICAL FORM
Granules.
White, free flowing, granules
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses and Ponies.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesic and anti-inflammatory action in musculo-skeletal
disorders and after
surgery.
4.3
CONTRAINDICATIONS
For specific information about the time which must elapse between
treatment and
competition, veterinary surgeons are advised to consult the authority
responsible for the
competition in question (eg. The Jockey Club in the case of racing in
the UK).
Do not exceed the stated dose or the duration of treatment.
Do not use in animals suffering from cardiac, hepatic or renal
disease, where there is a
possibility of gastro-intestinal ulceration or bleeding, or where
there is evidence of a
blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs concurrently or within 24 hours of each
other. Some
NSAIDs may be highly bound to plasma proteins and compete with other
highly bound
drugs, which can lead to toxic effects.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
Revised: 03 June 2008
AN: 02090/2007
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in any animal less than 6 weeks of age, or in aged animals may
involve additional
risk. If such use cannot be avoided, animals may require a reduced
dosage and careful
clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a
potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should